Chemo-immunotherapy before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and lenvatinib before surgery to treat esophageal squamous cell carcinoma that hasn't spread and can be removed. It aims to see if this approach can improve outcomes for patients with stage II to IVa disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old with esophageal squamous cell carcinoma that hasn't spread to other parts of the body and can be removed by surgery.
- You have not had any prior cancer treatment like chemotherapy, radiation, immunotherapy, or targeted therapy.
- You are in generally good health, with a performance status score of 0 or 1 (meaning you can do your daily activities without help).
- Your blood work shows adequate organ function, including normal blood cell counts, liver and kidney function, and no protein in the urine.
- You must not have other serious medical conditions like uncontrolled high blood pressure, heart problems, active infections, autoimmune diseases, or a history of other cancers in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the safety and effectiveness of combining two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (nab-paclitaxel) before surgery for people with a certain type of esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.